Again, thank you very much for the question.
At the time of the investment, it really was an investment in their vaccine candidate and looking to get an effective and safe vaccine to market as soon as possible.
The ownership structure and the challenge that it might present to them was not known at the time of the decision. It's probably worth mentioning that the PMI group owns a minority share in the company. It is majority controlled by Mitsubishi. It operates as an independent biomanufacturing company and, really, the focus was on getting a safe and effective vaccine to market as soon as possible.